Tata Group’s Arthritis Drug Deal with Vyome Holdings marks a major step in India’s growing biotech and pharmaceutical innovation space. The Arthritis Drug Deal involves Tata-backed Impetis Biosciences out-licensing two experimental drugs designed...
Biocon, Health Canada approval, and antifungal injection developments received a major boost after Biocon Pharma Ltd secured approval for Micafungin for Injection, strengthening the company’s presence in regulated international pharmaceuti...
Public Healthcare infrastructure in Delhi is set for a major expansion after the state government approved a Rs 805.99 crore medical college and hostel project in Dwarka. The upcoming facility, planned at the Indira Gandhi Hospital campus...
India’s private healthcare crisis is raising serious concerns about the future of affordable treatment for millions of patients. Several leading private hospital chains are reconsidering their participation in government-backed health schemes...
The Zydus Biologics plant has received seven observations from the US Food and Drug Administration (USFDA) after a recent inspection at the company’s injectable manufacturing facility in Ahmedabad. The inspection was carried out betwe...
Biocon Biologics has received five procedural observations from the U.S. Food and Drug Administration (USFDA) after an inspection at its Bengaluru manufacturing facility, drawing attention to the company’s regulatory compliance process...
India’s pharmaceutical sector is heading into a mixed March quarter, with drugmakers head into uneven Q4 as margins come under strain from US pricing pressure, loss of high-margin opportunities, and rising costs.
India’s Revised Safety Norms are set to change how hospitals grow, with the Centre easing long-standing restrictions on building height. The Bureau of Indian Standards (BIS) has removed the 45-metre cap on hospital structures under the newly...
The Centre has relaxed CME rules, medtech firms, and UCMPMD code requirements, making it easier for companies to organise training and educational programmes for healthcare professionals. The revised policy aims to reduce approval delays whil...
Indegene Q4 FY26 revenue crossed a major milestone, but profits told a different story. The company reported revenue of Rs 1,003 crore for the quarter, marking a strong 32.8 percent year-on-year growth and its first time breaching the...
.jpg)
.jpg)
, CDSCO.jpg)